Clinical trials: Vomiting
Preventing of Postoperative Nausea and Vomiting in Adults
A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults
The study is being conducted to evaluate the efficacy, and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults. To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting.
- Trial name
- NCT06475846
- Testing
- HRS5580, Ondansetron, blank preparation
- Where
- 2 sites in China
- Volunteers
- 235 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Nausea, Vomiting
A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)
This is a Phase 2, randomized, multicenter, parallel-group, double-blind, placebo-controlled study of various doses of SCH 619734 in subjects receiving cisplatin-based chemotherapy.
- Trial name
- NCT00394966
- Testing
- SCH 619734 Dose 1, SCH 619734 Dose 2, SCH 619734 Dose 3
- Volunteers
- 450 people
- Sponsor
- Schering-Plough
Nausea and Vomiting, Chemotherapy-Induced
A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).
This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.
- Trial name
- NCT00405080
- Testing
- GW679769 (Casopitant) oral tablets, Rifampin oral capsules
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
PONV
A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
A comparison of the efficacy of Amisulpride and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
- Trial name
- NCT05822713
- Testing
- Amisulpride
- Volunteers
- 516 people
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Nausea, Vomiting
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
- Conditions
- Nausea, Vomiting, Breast Neoplasms
- Trial name
- NCT00092196
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days
- Volunteers
- 820 people
- Sponsor
- Merck Sharp & Dohme LLC
Morning Sickness
A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
The primary objective of this study is to compare the efficacy of Diclegis for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo.
- Trial name
- PED-301 (NCT02045901)
- Testing
- Diclegis
- Where
- 8 sites in United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Duchesnay Inc.
CINV
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy
- Trial name
- NCT01857232
- Testing
- Ondansetron, Dexamethasone, Fosaprepitant
- Where
- Denmark
- Volunteers
- 342 people
- Sponsor
- Acacia Pharma Ltd
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Pain, Nausea
A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV
To determine the analgesic efficacy of CL-108 5 mg by comparison with placebo and the anti-emetic efficacy of CL-108 5 mg by comparison with hydrocodone 5 mg/acetaminophen 325 mg.
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT03657810
- Testing
- CL-108 5 mg, Norco
- Where
- 5 sites in United States
- Volunteers
- 349 people
- Sponsor
- Charleston Laboratories, Inc
Nausea and Vomiting, Chemotherapy-Induced
Cyclophosphamide Drug Interaction Study In Cancer Patients
This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
- Trial name
- NCT00334646
- Testing
- Oral GW679769, IV Cyclophosphamide 500-700mg/m2
- Where
- 5 sites in United States, New Zealand and 1 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Functional Dyspepsia
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar…
- Trial name
- NCT06217393
- Testing
- Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets
- Where
- 19 sites in Armenia, Malaysia and 3 more
- Volunteers
- 564 people
- Sponsor
- Abbott
Chemotherapy-induced Nausea and Vomiting
Re-examination Study of EMEND (Aprepitant) (MK-0869-184)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation.
- Trial name
- NCT01074255
- Testing
- EMEND
- Volunteers
- 3,546 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
This study looks at how to reduce nausea and vomiting in people taking KarXT which is used to treat mental health conditions like schizophrenia.
- Trial name
- NCT07681076
- Testing
- KarXT, Trimethobenzamide, Ondansetron
- Where
- 4 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Nausea and Vomiting, Postoperative
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
- Trial name
- NCT00326248
- Testing
- GW679769 (casopitant)
- Where
- 58 sites in United States, Canada and 9 more
- Volunteers
- 482 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-Induced Nausea and Vomiting
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone.
- Trial name
- NCT01376297
- Testing
- Netupitant and Palonosetron, Aprepitant, Palonosetron
- Where
- 75 sites in United States, Bulgaria and 8 more
- Volunteers
- 413 people
- Sponsor
- Helsinn Healthcare SA
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
The purpose of this study is provide confirmation of the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult women.
- Trial name
- NCT02025725
- Testing
- Metoclopramide Nasal Spray
- Where
- 50 sites in United States
- Volunteers
- 205 people
- Sponsor
- Evoke Pharma
Vomiting
12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting
This is a randomized, double blind, placebo controlled, multicenter study designed to assess the safety and efficacy of DDP225 in patients with chronic functional vomiting.
- Trial name
- NCT00252993
- Testing
- DDP225
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dynogen Pharmaceuticals
Gastroenteritis
Ondansetron Versus Metoclopramide in Treatment of Vomiting in Gastroenteritis
Is intravenous metoclopramid as effective as intravenous ondansetron in the treatment of persistent vomiting in patients with acute gastroenteritis.
- Trial name
- NCT01165866
- Testing
- Treatment 1. Metoclopramide, Treatment 2 Ondansetron
- Where
- Qatar
- Volunteers
- 170 people
- Sponsor
- Hamad Medical Corporation
Chemotherapy Induced Nausea and Vomiting
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients…
- Trial name
- NCT06065722
- Testing
- Akynzeo
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Simon Williamson Clinic
Chemotherapy-induced Nausea and Vomiting
A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to assess the efficacy and safety of SP-01 in chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic (ME or HE) multi-day…
- Trial name
- NCT01937156
- Testing
- SP-01 (Granisetron Transdermal Delivery System), Granisetron Hydrochloride Tablet
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Solasia Pharma K.K.